

[Chem. Pharm. Bull.]
36(11)4593—4596(1988)

Degradation of β -Lactamase Inhibitor (2*S*,3*R*,5*S*)-3-Methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic Acid 4,4-Dioxide (YTR-830H)¹⁾ in the Solid State: Structural Elucidation

EIJI MATSUSHIMA, KEN-ICHIRO YOSHIDA, RYOTARO AZUMA,
YOSHINORI MINAMI and TERUYOSHI MARUNAKA*

*Biological Research Laboratory, Taiho Pharmaceutical Co., Ltd.,
Hiraishi, Kawauchi-cho, Tokushima 771-01, Japan*

(Received April 30, 1988)

(2*S*,3*R*,5*S*)-3-Methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide (YTR-830H) is a new β -lactamase inhibitor. It was found that the thermal degradation of powdered or lyophilized samples of YTR-830H produced (*Z*)-3-methyl-4-(1*H*-1,2,3-triazol-1-yl)-2-butenic acid (YTR-830H-IV), 2-amino-3-methyl-3-sulfino-4-(1*H*-1,2,3-triazol-1-yl)-butyric acid (YTR-830H-II) and its related degradation products, and formylacetic acid (YTR-830H-III).

Keywords—(2*S*,3*R*,5*S*)-3-methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide (YTR-830H); β -lactamase inhibitor; solid-state degradation product; structural elucidation; (*Z*)-3-methyl-4-(1*H*-1,2,3-triazol-1-yl)-2-butenic acid (YTR-830H-IV)

Introduction

(2*S*,3*R*,5*S*)-3-Methyl-7-oxo-3-(1*H*-1,2,3-triazol-1-yl-methyl)-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid 4,4-dioxide, YTR-830H, is a new β -lactamase inhibitor, developed through the co-operation of R. G. Micetich and Taiho Pharm. Co. (Tokushima, Japan).²⁾

Combination therapy, utilizing this β -lactamase inhibitor with piperacillin, has been shown to extend the *in vitro* spectrum of β -lactam antibiotics to a number of resistant organisms. It has also been demonstrated to have relatively little intrinsic biological activity.³⁾

We have previously reported the stability of YTR-830H in buffer solutions, distilled water, aqueous NaOH solution and NaOH-saturated methanol solution.¹⁾ It was found that YTR-830H is degraded to 2-amino-3-methyl-3-sulfino-4-(1*H*-1,2,3-triazol-1-yl)-butyric acid (YTR-830H-II) and formylacetic acid (YTR-830H-III) through (*E*)-5-methyl-5-sulfino-6-(1*H*-1,2,3-triazol-1-yl)-3-aza-1-heptene-1,4-dicarboxylic acid (YTR-830H-I) as an intermediate, with the YTR-830H-II then proceeding to 1,2,3-triazole and several unidentified products (YTR-830H-IIa, -IIb, -IIc and -IId). The present paper describes the thermal degradation products of YTR-830H.

Experimental

Materials and Reagents— β -Lactamase inhibitor YTR-830H was supplied by our Synthetic Laboratory. Acetonitrile was of liquid chromatographic reagent grade. The CD₃OD used for the measurement of ¹H-nuclear magnetic resonance (¹H-NMR) spectra was obtained from Merck (Darmstadt, G.F.R.). The ion-pair chromatographic reagent, PIC-A® (Low UV), containing tetra-*n*-butyl ammonium salt, was obtained from Waters Assoc. (Milford, MA, U.S.A.). Other chemicals used were all purchased from Wako (Osaka, Japan).

CHP-20P resin (150–300 μm particle size) was obtained from Mitsubishi Chemical Industry (Tokyo, Japan). The PIC-A aqueous solution, used as a mobile phase, was prepared to 5 mM concentration by adding the contents of one vial (*ca.* 20 ml) of commercial PIC reagent to 1.01 of distilled water. The 10 mM sodium dihydrogenphosphate used as a mobile phase was adjusted to pH 3.0 by the addition of phosphoric acid.

Instruments—The infrared (IR) spectra were measured on a Hitachi 260-50 IR spectrophotometer (Tokyo, Japan) by the KBr tablet method. The ultraviolet (UV) spectra were recorded with a Shimadzu UV-265FW spectrophotometer (Kyoto, Japan). ^1H -NMR spectra were measured using a JEOL FX-100 NMR spectrometer coupled with an FAFT 70 data system and equipped with a Fourier transformer (Tokyo, Japan), using tetramethylsilane as an internal standard. A JEOL DX-300 mass spectrometer linked to a JMA-DA5100 data system was used for the measurement of electron impact and fast atom bombardment mass spectra (EI- and FAB-MS); the conditions were described in the previous report.¹⁾ A Shimadzu LC-6 high-performance liquid chromatographic system¹⁾ was used for the separation of degradation products.

High-Performance Liquid Chromatography (HPLC)—The separation of the thermal degradation products of YTR-830H formed in the solid state was carried out under the following conditions.

- i) HPLC Condition 1: Same as HPLC condition 1 described in the previous report.¹⁾
- ii) HPLC Condition 2: Column, Develosil ODS-5, 150 \times 4.6 mm i.d.; column temperature, room temperature; mobile phase, acetonitrile: 10 mM NaH_2PO_4 (pH 3.0)=5:95 (v/v); flow rate, 1.5 ml/min; and detector, UV 220 nm (0.08 a.u.f.s.).

Degradation of Powdered and Lyophilized Samples—The powdered (1 g) and lyophilized (25 mg) samples of YTR-830H in an airtight vial (55 \times 25 mm i.d.) containing dried air was stored at 60 $^\circ\text{C}$ for six months. Then the preparations were subjected to analysis under the HPLC conditions 1 and 2, and the previously described post-column alkalization¹⁾ to detect the degradation products.

Isolation of YTR-830H-IV—YTR-830H (1 g) which had been stored at 60 $^\circ\text{C}$ for six months was dissolved in 1 ml of distilled water. This solution was subjected to CHP-20P column chromatography (150–300 μm particle size, 200 \times 20 mm i.d., packed using 0.1% acetic acid solution); the column was washed with 100 ml of 0.1% acetic acid solution and subsequently with 150 ml of 0.1% acetic acid solution containing 30% methanol, and then eluted with 0.1% acetic acid solution containing 50% methanol. The eluate was evaporated to remove methanol and lyophilized to yield 6 mg of YTR-830H-IV as a white powder. FAB-MS m/z : 168 ($M+1$)⁺. EI-MS m/z : 168 ($M+1$)⁺, 139 ($M-N_2$), 122 ($M-COOH$), 121 ($139-H_2O$), 94 ($122-N_2$), 93 ($121-CO$), 82 ($121-C_2HN$), 69 ($C_2H_3N_3$), 53 (C_4H_5). IR (KBr): 1700 ($\nu_{C=O}$), 1660 ($\nu_{C=C}$) cm^{-1} . UV λ_{max} : 208 nm (H_2O), 219 nm (0.25 N NaOH). ^1H -NMR (CD_3OD) δ : 1.74 (d, $J=1.5$ Hz, 3- CH_3), 5.69 (s, 3- CH_2), 5.96 (q, $J=1.5$ Hz, 2- $\text{CH}=\text{}$), 7.56 (d, $J=1$ Hz, triazole 4- $\text{CH}=\text{}$), 8.01 (d, $J=1$ Hz, triazole 5- $\text{CH}=\text{}$).

Results and Discussion

Degradation of Powdered and Lyophilized Samples

Figure 1 shows the chromatograms obtained by HPLC under conditions 1 and 2 of the powdered and lyophilized samples of YTR-830H after storage at 60 $^\circ\text{C}$ for six months. The degradation products YTR-830H-II, YTR-830H-IIa, YTR-830H-III and 1,2,3-triazole were found. As described previously,¹⁾ YTR-830H-III could be detected by post-column alkalization. Furthermore, YTR-830H-IV, a new degradation product, was also detected. YTR-830H-IV was not detected following the degradation in various buffers, distilled water,




Fig. 1. Chromatograms under HPLC Conditions (A) 1 and (B) 2 of YTR-830H after Storage in the Solid State at 60 $^\circ\text{C}$ for 6 Months

a, YTR-830H; b, YTR-830H-II; c, YTR-830H-IIa; d, 1,2,3-triazole.

solution: this methyl ester showed a molecular ion peak of m/z 181 (M)⁺ in its EI-MS and approximately a 9% NOE (between CH_3 and $=CH$) in its 1H -NMR spectrum.

On the basis of the above results, YTR-830H-IV was identified as (*Z*)-3-methyl-4-(1*H*-1,2,3-triazol-1-yl)-2-butenic acid.

Presumed Degradation Pathways of YTR-830H

As shown in Chart 1, it can be postulated that there is another degradation pathway followed by YTR-830H undergoing thermal degradation in the solid state, compared with the degradation schemes determined for various buffer solutions, distilled water, aqueous NaOH solution and NaOH-saturated methanol.¹⁾

References

- 1) T. Marunaka, E. Matsushima, Y. Minami, K. Yoshida and R. Azuma, *Chem. Pharm. Bull.*, **36**, 4478 (1988).
- 2) R. G. Micetich, S. N. Maiti, P. Spevak, T. W. Hall, S. Yamabe, N. Ishida, M. Tanaka, T. Yamazaki, A. Nakai and K. Ogawa, *J. Med. Chem.*, **30**, 1469 (1987).
- 3) R. G. Micetich, T. W. Hall, S. N. Maiti, P. Spevak, S. Yamabe, N. Ishida, K. Ogawa, M. Tanaka, T. Yamasaki and A. Nakai, Proceedings of the 14th International Congress of Chemotherapy, Kyoto, Japan, 1985, p. 249; N. Ishida, A. Hyodo, C. Hanehara, Y. Miyake, Y. Kawaguchi and S. Yamabe, Proceedings of the 14th International Congress of Chemotherapy, Kyoto, Japan, 1985, p. 1274; M. R. Jacobs, S. C. Aronoff, S. Jøhanning, D. M. Shlaes and S. Yamabe, *Antimicrob. Agents Chemother.*, **29**, 980 (1986); M. R. Jacobs, S. C. Aronoff, S. Jøhanning and S. Yamabe, *J. Antimicrob. Chemother.*, **18**, 177 (1986); P. C. Appelbaum, M. R. Jacobs, S. K. Spangler and S. Yamabe, *Antimicrob. Agents Chemother.*, **30**, 789 (1986); F. Moosdeen, J. Keeble and J. D. Williams, *Reviews of Infectious Diseases*, **8**, supp. 5, S562 (1986).